Sharps Compliance Corp. (SMED) Expected to Post Earnings of -$0.01 Per Share

Sharps Compliance Corp. (SMED) Expected to Post Earnings of -$0.01 Per Share

Equities analysts forecast that Sharps Compliance Corp. (NASDAQ:SMED) will announce earnings of ($0.01) per share for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Sharps Compliance’s earnings, with the lowest EPS estimate coming in at ($0.02) and the highest estimate coming in at ($0.01). Sharps Compliance posted earnings of ($0.05) per share during the same quarter last year, which indicates a positive year over year growth rate of 80%. The business is expected to announce its next quarterly earnings report before the market opens on Wednesday, April 24th.

According to Zacks, analysts expect that Sharps Compliance will report full year earnings of $0.06 per share for the current financial year, with EPS estimates ranging from $0.04 to $0.07. For the next year, analysts anticipate that the company will post earnings of $0.18 per share, with EPS estimates ranging from $0.08 to $0.35. Zacks’ earnings per share calculations are an average based on a survey of research firms that cover Sharps Compliance.

Sharps Compliance (NASDAQ:SMED) last posted its earnings results on Wednesday, January 23rd. The industrial products company reported $0.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.02. The business had revenue of $12.39 million during the quarter, compared to analyst estimates of $11.40 million. Sharps Compliance had a negative return on equity of 0.21% and a negative net margin of 0.13%. During the same quarter in the previous year, the firm earned $0.01 EPS.

Separately, Zacks Investment Research downgraded Sharps Compliance from a “buy” rating to a “hold” rating in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Sharps Compliance currently has an average rating of “Hold” and a consensus target price of $4.33.

NASDAQ:SMED remained flat at $$3.59 during mid-day trading on Tuesday. The company had a trading volume of 248 shares, compared to its average volume of 8,598. The company has a market cap of $57.94 million, a P/E ratio of -89.75, a price-to-earnings-growth ratio of 3.40 and a beta of 0.16. Sharps Compliance has a one year low of $2.97 and a one year high of $4.77. The company has a quick ratio of 2.02, a current ratio of 2.63 and a debt-to-equity ratio of 0.05.

An institutional investor recently raised its position in Sharps Compliance stock. Quantum Capital Management increased its position in Sharps Compliance Corp. (NASDAQ:SMED) by 7.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 519,346 shares of the industrial products company’s stock after purchasing an additional 34,890 shares during the period. Sharps Compliance accounts for 1.0% of Quantum Capital Management’s portfolio, making the stock its 25th biggest position. Quantum Capital Management owned approximately 3.22% of Sharps Compliance worth $1,792,000 at the end of the most recent quarter. Institutional investors own 20.55% of the company’s stock.

About Sharps Compliance

Sharps Compliance Corp. provides medical, pharmaceutical, and hazardous waste management services in the United States. It offers Sharps Recovery System for the containment, transportation, treatment, and tracking of medical waste and used healthcare materials generated outside the hospital and health care facility settings; TakeAway Medication Recovery System, a solution that facilitates the proper disposal of unused medications; MedSafe, a solution for the safe collection, transportation, and proper disposal of unwanted and expired prescription medications; and ComplianceTRAC, a Web-based compliance and training program.

Recommended Story: What is a trade deficit?

Get a free copy of the Zacks research report on Sharps Compliance (SMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment